Pathology research identifies potential new target for preventing brain metastasis

by Jamie Botta, Duke University

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Research led by professor of pathology Mikhail Nikiforov, Ph.D., has identified a key mechanism that helps cancer cells spread to the brain, which may lead to a new target for future therapies. The findings were published in the journal Cell Reports in the article "SERINC2-mediated phosphatidylserine remodeling activates protrusion-localized AXL signaling to promote brain metastasis."

Brain metastases are among the most challenging complications of cancer, often leading to poor outcomes and limited treatment options. In the study, researchers investigated how tumor cells gain the ability to migrate, invade surrounding tissue and create new tumors in the brain.

SERINC2 fuels invasion and tumor growth

The team identified a protein called SERINC2 as a critical driver of this process. Their research demonstrated that SERINC2 promotes the accumulation of phosphatidylserine, a lipid found in cell membranes, within specialized cellular extensions that cancer cells use for movement and invasion. This accumulation activates AXL, a signaling protein known to regulate cancer cell motility and metastatic behavior.

The study also uncovered another role for SERINC2 in shaping the tumor microenvironment. By promoting the accumulation and release of phosphatidylserine, SERINC2 helps cancer cells communicate with immune cells in the brain, changing their behavior in ways that support tumor growth. The researchers found that lowering SERINC2 levels made cancer cells less invasive and slowed brain tumor growth in animal models.

"These findings provide important new insights into the biological mechanisms that drive brain metastasis," said Nikiforov. "By identifying SERINC2 as a key regulator of both cancer cell invasion and interactions with the brain microenvironment, this work highlights a potential new therapeutic target for slowing or preventing metastatic disease."

As researchers continue to seek more effective treatments for metastatic disease, the study provides a foundation for future investigations into therapies that target SERINC2 and related signaling pathways.

Publication details

Zhibo Yan et al., SERINC2-mediated phosphatidylserine remodeling activates protrusion-localized AXL signaling to promote brain metastasis, Cell Reports (2026). DOI: 10.1016/j.celrep.2026.117962

Journal information: Cell Reports

Key medical concepts

Brain MetastasePhosphatidylserine

Clinical categories

Oncology Provided by Duke University Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Pathology research identifies potential new target for preventing brain metastasis (2026, October 27) retrieved 27 October 2026 from https://medicalxpress.com/news/2026-10-pathology-potential-brain-metastasis.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.